EuroEspes S.A. | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 10.2M
Total Liabilities 4.0M
Shareholders Equity 6.2M
Debt to Equity 0.65

Cash Flow Metrics

Revenue & Profitability Trend

EuroEspes S.A Income Statement From 2019 to 2023

Metric20232022202120202019
Revenue i3.0M3.3M3.3M2.5M2.4M
Cost of Goods Sold i242.8K217.2K101.8K141.0K267.0K
Gross Profit i2.7M3.1M3.2M2.4M2.1M
Gross Margin % i91.8%93.4%96.9%94.4%88.8%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i-1.4M1.0M623.1K-
Other Operating Expenses i1.6M1.6M1.2M753.6K990.0K
Total Operating Expenses i1.6M2.9M2.2M1.4M990.0K
Operating Income i-1.4M-956.6K-247.4K-351.0K-826.7K
Operating Margin % i-47.6%-29.0%-7.5%-13.9%-34.8%
Non-Operating Items
Interest Income i--154.7K21-
Interest Expense i220.9K103.8K94.8K82.9K96.8K
Other Non-Operating Income-----
Pre-tax Income i-2.1M-1.2M-177.0K-429.5K-956.1K
Income Tax i--6.5K-18.1K384.2K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-2.1M-1.2M-183.4K-411.3K-1.3M
Net Margin % i-72.3%-35.3%-5.6%-16.3%-56.4%
Key Metrics
EBITDA i-408.3K-102.2K510.9K229.7K-221.0K
EPS (Basic) i-€-0.10€-0.02€-0.04€-0.12
EPS (Diluted) i-€-0.10€-0.02€-0.04€-0.12
Basic Shares Outstanding i-11608566115979841157329610547661
Diluted Shares Outstanding i-11608566115979841157329610547661

Income Statement Trend

EuroEspes S.A Balance Sheet From 2019 to 2023

Metric20232022202120202019
Assets
Current Assets
Cash & Equivalents i422.9K971.1K2.0M2.2M2.3M
Short-term Investments i2.5K2.5K17.2K17.6K20.5K
Accounts Receivable i248.0K374.1K322.1K183.5K189.3K
Inventory i342.8K475.0K549.8K431.6K354.7K
Other Current Assets-----
Total Current Assets i1.1M2.0M2.9M3.0M3.0M
Non-Current Assets
Property, Plant & Equipment i10.4M10.5M10.0M9.9M9.9M
Goodwill i3.0M3.6M4.0M3.8M3.3M
Intangible Assets i3.0M3.6M4.0M3.8M3.3M
Long-term Investments09.9K15.0K0-
Other Non-Current Assets-151-1--1
Total Non-Current Assets i6.9M8.3M9.3M8.7M8.4M
Total Assets i7.9M10.2M12.3M11.7M11.4M
Liabilities
Current Liabilities
Accounts Payable i117.1K179.2K165.8K218.6K136.5K
Short-term Debt i4.0M1.8M810.5K859.6K1.2M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i5.0M2.6M1.6M1.4M1.7M
Non-Current Liabilities
Long-term Debt i28.1K2.6M3.2M2.8M2.1M
Deferred Tax Liabilities i2.7K3.0K3.6K5.0K5.6K
Other Non-Current Liabilities--1.2M---
Total Non-Current Liabilities i44.6K1.5M3.3M2.9M2.2M
Total Liabilities i5.0M4.0M4.8M4.3M3.9M
Equity
Common Stock i7.1M7.1M7.1M7.1M6.5M
Retained Earnings i-2.1M-1.1M-183.4K-411.3K-1.3M
Treasury Stock i143.2K110.9K107.6K151.2K168.3K
Other Equity-----
Total Shareholders Equity i2.9M6.2M7.4M7.4M7.4M
Key Metrics
Total Debt i4.0M4.4M4.0M3.6M3.3M
Working Capital i-3.9M-586.2K1.4M1.6M1.3M

Balance Sheet Composition

EuroEspes S.A Cash Flow Statement From 2019 to 2023

Metric20232022202120202019
Operating Activities
Net Income i-2.1M-1.2M-177.0K-429.5K-956.1K
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i899.9K-236.9K-277.1K-216.0K32.3K
Operating Cash Flow i-1.0M-2.2M-1.1M-825.0K-987.2K
Investing Activities
Capital Expenditures i-167.4K-554.8K-94.1K-60.3K-230.6K
Acquisitions i-----
Investment Purchases i-557.5K0-560.0K00
Investment Sales i10.1K----
Investing Cash Flow i-714.8K-554.8K-654.1K-60.3K-230.6K
Financing Activities
Share Repurchases i-34.2K-101.9K-152.3K-85.6K-142.0K
Dividends Paid i-----
Debt Issuance i57.6K995.6K1.0M1.5M764.2K
Debt Repayment i-57.0K-634.9K-687.5K-1.2M-1.1M
Financing Cash Flow i-33.6K364.7K491.0K312.8K-285.8K
Free Cash Flow i32.8K-1.4M-184.1K-429.9K-804.6K
Net Change in Cash i-1.8M-2.4M-1.2M-572.5K-1.5M

Cash Flow Trend

EuroEspes S.A Key Financial Ratios

Valuation Ratios

Price to Sales 2.12

Profitability Ratios

Profit Margin 91.78%
Operating Margin -64.77%
Return on Equity -73.83%
Return on Assets -26.90%

Financial Health

Current Ratio 0.77
Debt to Equity 0.70

Per Share Data

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
eep6.3M---73.83%91.78%0.70
Clinica Baviera S.A 698.2M18.177.8346.33%13.51%70.72
Pangaea Oncology 58.7M-3.22-29.97%-37.18%23.04
Grifols, S.A 7.8B29.191.694.99%4.00%126.87
Laboratorios 2.7B20.754.8825.01%17.66%22.50
Almirall S.A 2.2B102.601.511.45%2.02%26.47

Financial data is updated regularly. All figures are in the company's reporting currency.